Model | Number of patients included in the analysis* | Treatment difference†‡ | 95% CI | SE |
---|---|---|---|---|
Number of ETDRS letters | ||||
Method (2), model 2: Post-treatment values only | 517 | −1.7 | (−4.8 to 1.4) | 1.55 |
Method (3), model 3: Change from baseline | 517 | −0.8 | (−3.3 to 1.6) | 1.25 |
Method (1), model 1: Post-treatment values with baseline value as a covariate | 517 | −1.1 | (−3.4 to 1.3) | 1.21 |
*Although 525 patients reached the 24-month visit in the IVAN trial, BCVA data are missing for 8 of these patients.
†Difference in mean BCVA (bevacizumab—ranibizumab).
‡The results presented differ from the published results.5 For illustrative purposes, only the drug treatment was included in the model; BCVA measured during follow-up and other factors included models used to obtain the published results have not been included.
BCVA, Best Corrected Visual Acuity.